The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension by Falk, Jeremy A et al.
© 2010 Falk et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2010:6 273–280
Vascular Health and Risk Management
273
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The emergence of oral tadalafil as a once-daily 
treatment for pulmonary arterial hypertension
Jeremy A Falk 
Kiran J Philip 
Ernst R Schwarz
Cedars Sinai Women’s Guild Lung 
Institute, Cedars Sinai Heart Institute, 
Cedars Sinai Medical Center,  
Los Angeles, CA, USA
Correspondence: Ernst R Schwarz, 
Cedars Sinai Heart Institute, CSMC, 8700 
Beverly Boulevard., Ste. 6215, Los Angeles, 




Abstract: Pulmonary hypertension (PH) is found in a vast array of diseases, with a minority 
representing pulmonary arterial hypertension (PAH). Idiopathic PAH or PAH in association 
with other disorders has been associated with poor survival, poor exercise tolerance, progres-
sive symptoms of dyspnea, and decreased quality of life. Left untreated, patients with PAH 
typically have a progressive decline in function with high morbidity ultimately leading to death. 
Advances in medical therapy for PAH over the past decade have made significant inroads into 
improved function, quality of life, and even survival in this patient population. Three classes 
of pulmonary artery-specific vasodilators are currently available in the United States. They 
include prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 (PDE5) 
inhibitors. In May 2009, the FDA approved tadalafil, the first once-daily PDE5 inhibitor for 
PAH. This review will outline the currently available data on tadalafil and its effects in patients 
with PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a rare disorder with reports estimating its 
prevalence at between 15 and 52 cases per one million patients.1,2 Pulmonary hyper-
tension (PH) has been defined differently based on the modality used to measure 
pulmonary pressures and hemodynamics. Generally considered the gold standard for 
the assessment of pulmonary hypertension, direct pulmonary artery catheterization 
with pressure measurements is preferred to less invasive techniques to confirm the 
suspected diagnosis. PAH is defined by a mean pulmonary artery pressure (mPAP) of 
more than 25 mmHg at rest or of more than 30 mmHg with exercise. In PAH, pulmo-
nary capillary wedge pressure or left ventricular end diastolic pressure (in the absence 
of a mitral valve stenosis) is usually less than 15 mmHg.3,4
Traditional classification of pulmonary hypertension largely differentiated patients 
with idiopathic or primary cases from patients with PH from secondary causes. This 
classification scheme had many limitations as it did not adequately describe underly-
ing mechanisms of the disease and their implications for potential treatment options, 
based on the pathophysiology of the underlying conditions. In 1998, the World 
Health Organization (WHO) created a classification scheme, often referred to as the 
“Evian Classification,” which described a variety of disorders causing pulmonary 
hypertension based on different mechanisms.5 This classification scheme was further 
refined in 2003 in Venice and most recently in 2008 at the 4th World Symposium on 
Pulmonary Hypertension in Dana Point, California (Table 1).6Vascular Health and Risk Management 2010:6 274
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The current WHO classification scheme divides PH into 
five groups: Group 1 represents disorders resulting in PH 
such as idiopathic PH, familial forms of PH, drug/toxin-
induced PH, PH associated with connective tissue diseases, 
HIV infection, portal hypertension, congenital heart disease, 
schistosomiasis, and chronic hemolytic anemia, as well as 
persistent pulmonary hypertension of the newborn. Group 2 
includes causes of PH as a result of left sided heart disease. 
Group 3 includes patients with chronic hypoxemia and/or 
lung disease. Chronic thromboembolic disease is categorized 
in group 4 and group 5 is reserved for those diseases which 
have multifactorial mechanisms leading to PH.
Treatments for PAH
Most recent pharmacologic treatments of PH have focused 
on group 1 or PAH. In fact, of the current Food and Drug 
Administration (FDA)-approved agents for the treatment 
of PH, all are approved for PAH (group 1) only. Current 
pharmacologic treatment for PAH include calcium channel 
blockers, prostanoids, endothelin receptor antagonists (ERA), 
and phosphodiesterase type 5 (PDE5) inhibitors (Table 2). 
The use of calcium channel blockers in PAH has generally 
been restricted due to limited benefits, significant side effects, 
and relatively narrow indications.3 Calcium channel blockers 
appear to benefit mainly patients with PAH with a positive 
vasodilator challenge, however, even in those patients, the 
long-term response to calcium channel blocker treatment is 
variable.7
ERAs currently approved for use in the US include 
bosentan and ambrisentan. Endothelin-1 is a potent vaso-
constrictor and mitogen likely causing vascular remodeling 
in susceptible individuals. Both bosentan and ambrisentan 
have been shown to significantly improve exercise capacity 
and hemodynamics in PAH.8–12 Bosentan is a nonselective 
endothelin receptor blocker, whereas ambrisentan blocks 
Table 1 Dana Point classification of pulmonary hypertension 
(PAH), 2008
1.  Pulmonary arterial hypertension (PAH)
1.1.  Idiopathic PAH
1.2.  Heritable
1.2.1.  BMPR2 (bone morphogenetic protein receptor type 2)
1.2.2.   ALK1 (activin receptor-like kinase type 1), endoglin (with or 
without hereditary hemorrhagic telangiectasia)
1.2.3.  Unknown
1.3.  Drug- and toxin-induced
1.4. Associated with
1.4.1.  Connective tissue diseases
1.4.2.  HIV infection
1.4.3.  Portal hypertension
1.4.4.  Congenital heart diseases
1.4.5.  Schistosomiasis
1.4.6.  Chronic hemolytic anemia
1.5.  Persistent pulmonary hypertension of the newborn
1.    Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH)
2.  Pulmonary hypertension owing to left heart disease
2.1.  Systolic dysfunction
2.2.  Diastolic dysfunction
2.3. Valvular disease
3.  Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1.  Chronic obstructive pulmonary disease
3.2.  Interstitial lung disease
3.3.    Other pulmonary diseases with mixed restrictive and obstructive 
pattern
3.4.  Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6.  Chronic exposure to high altitude
3.7.  Developmental abnormalities
4.  Chronic thromboembolic pulmonary hypertension (CTEPH)
5.  Pulmonary hypertension with unclear multifactorial mechanisms
5.1.  Hematologic disorders: myeloproliferative disorders, splenectomy
5.2.    Systemic disorders: sarcoidosis, pulmonary Langerhans cell histio-
cytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3.    Metabolic disorders: glycogen storage disease, Gaucher disease, 
thyroid disorders
5.4.    Others: tumoral obstruction, fibrosing mediastinitis, chronic renal 
failure on dialysis
Notes: This is a recently updated classification scheme of pulmonary hypertension 
which emphasizes underlying pathophysiology and underlying implications for treat-
ment. Adapted with permission from Simonneau G, Robbins IM, Beghetti M, et al. 
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 
Suppl):S43–54.6 Copyright © 2009 Elsevier.
Table 2 FDA-approved medications for pulmonary arterial 
  hypertension
Medication Dose/Route
Epoprostenol (Flolan®) Start 2 ng/kg/min IV and titrate to 
clinical effect
Treprostinil (Remodulin®/Tyvaso®) 0.625–40 ng/kg/min IV/SQ  
18–54 µg inhaled QID
Iloprost (Ventavis®) 2.5–5 µg nebulized inhaled solution 
to max of 9 doses/day
Ambrisentan (Letairis®) 5–10 mg PO daily
Bosentan (Tracleer®) 62.5–125 mg PO BID
Sildenafil (Revatio®) 20 mg PO TID
Tadalafil (Adcirca®) 40 mg PO daily
Notes: Seven medications are FDA approved for the treatment of PAH. Three classes 
of medications are represented here: prostanoids (epoprostenol, treprostinil, and 
iloprost), endothelin receptor antagonists (ambrisentan and bosentan), and phospho-
diesterase type 5 inhibitors (sildenafil and tadalafil).Vascular Health and Risk Management 2010:6 275
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only endothelin-A receptors. Liver function abnormalities 
have been noted with ERAs, in particular with bosentan, thus 
monthly liver function testing is required.3
Both parenteral and inhaled forms of prostacyclins 
are currently available for the treatment of PAH. Patients 
with PAH under produce prostacyclin, which functions to 
vasodilate, inhibit vascular proliferation, and inhibit platelet 
aggregation. Epoprostenol, a synthetic prostacyclin, was the 
first FDA-approved medication for the treatment of PAH. 
It remains the treatment of choice for advanced disease. 
Epoprostenol has a very short half-life and must be given 
continuously with an intravenous pump, typically with 
a starting dose of 2 ng/kg/min intravenously and titrated 
upwards to desired clinical effect. Ambulatory pumps have 
made it possible to treat patients with severe PAH as outpa-
tients.13 Epoprostenol has been shown to improve quality of 
life, exercise capacity, hemodynamics and even survival in 
PAH.14–17 Side effects include flushing, body aches, hypo-
tension, and jaw pain. Treprostinil, available in intravenous, 
subcutaneous, and inhaled formulations, has a longer half-
life than epoprostenol, thus allowing a wide variety of routes 
of delivery and may aid in improving compliance.18–20
PDE5 inhibitors have recently become an attractive 
first-line choice in the treatment of milder forms of PAH. 
Sildenafil was first FDA approved in the US for the treat-
ment of erectile dysfunction (ED) in 1998. After its release 
for the use in ED, sildenafil was found to be an effective 
pulmonary artery vasodilator.21–23 In 2005, sildenafil was 
approved for use in PAH at a dose of 20 mg 3 times daily, 
based in large part to the SUPER trial.24 There has been 
debate about the appropriate dosing of sildenafil for PAH 
as many studies have used dosing several-fold higher than 
the current FDA approved dosing.25–31 While a clear dose-
response effect of escalating dosing of sildenafil has not 
been shown in terms of improvements in exercise capacity, 
quality of life, or hemodynamics, long-term data in patients 
receiving 80 mg 3 times daily for 1 year have shown sus-
tained benefit with minimal adverse effects.24 Similar data 
for the 20 mg dose do not exist. Additionally, when used 
in combination with ERAs, it has been shown that there 
are decreased plasma levels of sildenafil, providing more 
rationale for higher dosages of sildenafil.32 Sildenafil has 
been shown to improve symptoms of PAH, improve exercise 
tolerance, improve hemodynamics, and to improve quality 
of life.24,28,29 Sildenafil inhibits the breakdown of cyclic gua-
nosine monophosphate (cGMP) thus increasing the effects 
of nitric oxide (NO) resulting in pulmonary vasodilation 
and inhibition of smooth muscle growth. The mechanism 
of action of PDE5 inhibitors will be discussed in more 
detail later. Tadalafil, another PDE5 inhibitor approved for 
PAH earlier this year, is a once daily medication used at a 
dose of 40 mg daily. Tadalafil, like sildenafil and vardenafil, 
was originally developed and marketed as a pharmacologic 
treatment for erectile dysfunction. Vardenafil appears to 
be less efficacious than either sildenafil or tadalafil for the 
treatment of PAH.33 Tadalafil’s longer half-life of 17.5 hours 
compared with that of sildenafil at 4 to 5 hours allows for 
a once-daily dosing.
PDE-5 inhibitors for the treatment 
of erectile dysfunction
Sildenafil was FDA approved in 1998 as the first PDE5 
inhibitor for the treatment of ED. Shortly after this, two 
other PDE5 inhibitors, tadalafil and vardenafil, were 
approved for the treatment of ED. While very few compara-
tive data exist for the various PDE5 inhibitors, there is a 
large body of double-blind placebo-controlled trials for 
the various agents.34 A recent meta-analysis showed con-
sistently beneficial short-term efficacy of PDE5 inhibitors 
in the treatment of ED with good safety profiles.34 Efficacy 
of treatment for ED is typically based on several validated 
measures of male sexual performance.34 The International 
Index of Erectile Function Erectile Functional Domain 
(IIEF EF) is a scoring system numbered 1–30 with higher 
numbers correlating with improved sexual function.35 
Another assessment tool is the use of questions 2 and 3 of 
the Sexual Encounter Profile (SEP), which ask first whether 
or not an adequate erection is obtained to initiate sexual 
intercourse and second whether or not intercourse is able 
to be completed.36 The Global Assessment Question (GAQ) 
asks, “Has the treatment you have been taking during this 
study improved your erection?”36
Approximately 28 randomized controlled trials (RCTs) 
observing the efficacy of tadalafil in ED have been recently 
identified.34 Two recent multi-centered placebo-controlled 
studies showed marked improvements in sexual performance 
with the addition of tadalafil given at a daily dose of 20 mg.37,38 
Skoumal et al randomized 443 men with ED to receive either 
tadalafil or placebo.37 Patients in the tadalafil group had sig-
nificant improvements in sexual function as measured by IIEF 
EF, SEP, and GAQ. In fact, 64% of patients receiving tadalafil 
had normal IIEF EF domain scores as opposed to only 16% 
for those receiving placebo. Porst et al studied 348 patients 
randomized to tadalafil or placebo for two 4-week treatment 
intervals.38 Patients were asked to attempt sexual intercourse 
24 and 36 hours after dosing with a primary endpoint being Vascular Health and Risk Management 2010:6 276
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the ability to complete sexual intercourse to completion. At 
36 hours, 59.2% of patients receiving tadalafil were able 
to complete intercourse compared with only 28.3% in the 
placebo arm, P  0.001. Similar results were observed at 
24 hours with successful intercourse reported as 52.9% and 
29.1%, respectively (P  0.001). Another study conducted 
at 15 US centers randomized 287 patients to receive once-
daily tadalafil at 5 mg, 2.5 mg, or placebo for 24 weeks.39 
Primary endpoint was a change in IIEF EF Domain score and 
response to SEP question 2 and 3. Significant improvements 
in ED were reported in all 3 endpoints with low incidence 
of adverse events.
The longer half-life of tadalafil (17.5 hours) when com-
pared with sildenafil (4 hours) may represent an attractive 
option to some patients as it may allow for less frequent 
dosing and a more sustained benefit. An unbiased, rigorously 
designed head to head trial among currently approved PDE5 
inhibitors for the treatment of ED does not currently exist. 
Four head to head trials of varying quality are currently pub-
lished, of which three were funded by Eli Lilly.40–43 Eardley 
and colleagues conducted a 12-week, open-label, cross-over 
study comparing tadalafil (10 or 20 mg) to sildenafil (25 mg, 
50 mg, or 100 mg).40 No differences were found in IIEF EF 
domain or SEP 2; however there was a small but statistically 
significant difference in SEP 3 responses favoring tadalafil 
(72% vs. 77%, P = 0.003). Additionally, at the conclusion of 
the study, 71% of patients preferred tadalafil to sildenafil. Two 
other double-blinded cross-over studies comparing sildenafil 
50 mg and tadalafil 20 mg showed similar patient prefer-
ence for tadalafil at the conclusion of the study; however, no 
benefit in efficacy was reported41,42 In a single non-industry 
sponsored comparison trial of sildenafil (100 mg), vardenafil 
(20 mg), and tadalafil (20 mg), 132 patients were prospec-
tively enrolled in an open-label, cross over trial over 45 to 
60 days with patient drug preference the primary outcome.43 
At the end of the trial, 52% preferred tadalafil, 28% chose 
sildenafil, and 20% chose tardenafil. In terms of efficacy, 
tadalafil was statistically better than vardenafil measured both 
by IIEF and the Erectile Dysfunction Inventory for Treatment 
Satisfaction (EDITS) Questionnaire. A statistically signifi-
cant difference in favor of tadalafil was also observed when 
compared to sildenafil as measured by the EDITS question-
naire. While there appears to be a trend towards the superior-
ity of tadalafil over other PDE5 inhibitors for the treatment 
of ED, these results must be interpreted with caution. Half 
of these studies were open label and therefore subject to 
potential patient and investigator bias.40,43 Additionally, two 
studies used a maximum dose of sildenafil of 50 mg, which 
may represent a lower effective dose when compared directly 
with 20 mg of tadalafil.41,42
Pharmacology of tadalafil
Many potential targets for therapeutic intervention in PAH 
have been identified.44 NO formation in pulmonary artery 
endothelium is needed to promote pulmonary artery vaso-
dilation and inhibition of smooth muscle cell prolifera-
tion.45 The production of cyclic guanosine monophosphate 
(cGMP) by activation of guanylate cyclase by NO in turn 
activates protein kinase G (PKG) that decreases pulmo-
nary artery smooth muscle cell calcium and potassium 
levels leading to pulmonary artery vasodilation, decreased 
smooth muscle cell proliferation, and increased apoptosis 
of pulmonary artery smooth muscle cells.31 Patients with 
PAH have been shown to have both decreased nitric oxide 
production from the pulmonary artery endothelium and 
to have increased PDE5 expression in the pulmonary 
artery smooth muscle cells.46–48 The combined effects of 
decreased nitric oxide production and increased PDE5 
expression ultimately promote pulmonary artery vaso-
constriction and increased pulmonary vascular resistance. 
As PDE5 leads to degradation of cGMP, a selective 
PDE5 inhibitor would have numerous downstream ben-
efits including pulmonary artery vasodilation, decreased 
pulmonary vascular resistance and ultimately increased 
cardiac output. Additionally, PDE5 inhibitors may aug-
ment right ventricular function though their inhibition of 
phosphodiesterase 3.49
Phosphodiesterase type 5 is located primarily in 
pulmonary artery smooth muscle cells and in the penile 
circulation. Its main role is to degrade cGMP located in 
these tissues. The relative paucity of PDE5 in the systemic 
vasculature makes this an attractive therapeutic target as one 
would expect minimal systemic vasodilation as opposed to 
nonselective vasodilators such as calcium channel block-
ers which cause prohibitive hypotension in most patients 
with PAH.3
Serum concentrations of tadalafil reach a maximum 2 to 
8 hours after ingestion of 40 mg with a mean terminal half-
life of 35 hours in patients with PAH. Tadalafil is predomi-
nantly metabolized by the liver by CYP3A and eliminated 
primarily in the feces and urine.50,51 Unlike sildenafil, it is 
recommended that patients with mild-to-moderate renal or 
hepatic dysfunction undergo a dose adjustment to 20 mg 
daily.31 As tadalafil is metabolized by CYP3A, inhibitors 
of the enzyme such as clarithromycin may lead to elevated 
serum concentrations.50 Combined usage of bosentan and Vascular Health and Risk Management 2010:6 277
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tadalafil has been shown to lead to a 41.5% decrease in the 
serum levels of tadalafil with no effect on bosentan.52 Similar 
effects of combined use of tadalafil and ambrisentan have 
not been observed.53
PDE-5 inhibition for the treatment 
of PAH
Numerous studies have shown that sildenafil is efficacious 
in improving hemodynamics, improving exercise tolerance, 
and improving quality of life.21–24,28,29 Limited by study size 
and design, sildenafil, has not been shown to alter the natu-
ral history of PAH or to improve survival. Sildenafil’s short 
half-life necessitates multiple daily dosing schedules and 
the currently approved dose of 20 mg 3 times daily may be 
inadequate for some patients.
Tadalafil has a longer half-life than sildenafil, thus 
allowing once-daily dosing. Starting in 2004, scattered case 
reports and small case series detailed the successful use of 
tadalafil for patients with PAH. An initial report in 2004 
by Palmieri et al detailed the use of 20 mg tadalafil given 
every other day in a 72-year-old female patient with PAH 
who failed epoprostenol infusion.54 The patient ultimately 
showed improvements in hemodynamics (pulmonary artery 
systolic pressure by echocardiogram went from 105 mmHg 
at baseline to 65 mmHg six months later), functional class 
(New York Heart Association class IV to II over 6 months), 
and improved gas exchange (partial pressure of oxygen 
to fraction of inhaled oxygen ratio went from 150 to 
300 mmHg). Several other case reports using similar doses 
had similar results: In 2008, Tay and colleagues reported a 
case series of 12 patients with PAH who were voluntarily 
changed from sildenafil at a dose of 100 to 150 mg/day to 
10 to 20 mg/day of tadalafil.55 Two small series describing 
the use of combination therapy with tadalafil have been 
published. The first published in 2008 by Bendayan et al 
details the combined use of prostacyclins and tadalafil. The 
addition of tadalafil to prostacyclins improved the 6-minute 
walk distance by nearly 60 m and improved functional status 
in 3 of 4 patients.56 Faruqi and colleagues reported the use of 
combined tadalafil and sitaxentan (a selective ERA approved 
in Europe and Australia) in 3 patients with PAH.57 Modest 
benefits in mean pulmonary artery pressure and 6-minute 
walk distance were noted after a minimum of 6 months, 
and, importantly, no serious adverse effects were reported. 
Given the clinical success of sildenafil in the treatment of 
PAH and the observed effects of small case series utilizing 
tadalafil, larger, prospective trials involving tadalafil were 
inevitable.
Comparisons between PDE-5 
inhibitors
In general, head to head comparisons of various PDE5 inhibi-
tors and their effect on the pulmonary circulation are lacking. 
Ghofrani et al compared the acute effects on hemodynamics 
and gas exchange of sildenafil (50 mg), vardenafil (10 mg and 
20 mg), and tadalafil (20 mg, 40 mg, and 60 mg) on patients 
with PAH.33 60 patients with New York Heart Association 
(NYHA) class II to IV symptoms were randomized to receive 
sildenafil, vardenafil, or tadalafil acutely after receiving 
short-term inhaled NO. After 120 minutes, all three PDE5 
inhibitors showed significant reductions in mean pulmonary 
artery pressure with a range of -10.0 mmHg to -18.3 mmHg. 
Only sildenafil and tadalafil were shown to be selective pul-
monary vasodilators rather than systemic vasodilators (change 
in PVR/SVR ratio of -9.3 to -16.0), and only sildenafil was 
shown to improve oxygenation with an increase in the par-
tial pressure of arterial oxygen of 8.9 mmHg. The authors 
postulated that the varying effects on hemodynamics and 
oxygenation were a result of different affinities of the drugs 
for other PDE subgroups other than 5, which may affect the 
pulmonary and systemic vasculature differently.
Clinical trials of tadalafil in PAH
In the only randomized, placebo-controlled study examining 
the use of tadalafil in PAH, Galiè and colleagues reported 
the effects of tadalafil alone or in combination with bosentan 
in the treatment of PAH (PHIRST trial).58 Four hundred and 
six patients were randomized to placebo, 2.5, 10, 20, or 
40 mg of tadalafil daily and followed for 16 weeks. Fifty-three 
percent of enrolled patients were taking bosentan at the time 
of enrollment. The primary endpoint was the change from 
baseline in the 6-minute walk test (6MWT) (Figure 1). Only 
patients randomized to 40 mg of tadalafil achieved the prede-
termined level of statistical significance (P  0.01) with an 
improvement in 6MWT of 33 m (95% CI, 15–50 m). Patients 
not taking bosentan improved by 44 m (95% CI, 20–69 m), 
and those taking bosentan improved by 23 m (95% CI -2 to 
48 m). A review of secondary endpoints indicated improve-
ments in time to clinical worsening, incidence of clinical 
worsening and health related quality of life. The authors 
suggested a possible drug–drug interaction with bosentan 
and tadalafil resulting in lower plasma levels of tadalafil, 
thus explaining the blunted response of tadalafil when used 
in combination with bosentan.52,58
Data from a long-term extension study of the PHIRST 
trial has yet to be published.58 Tadalafil was generally well Vascular Health and Risk Management 2010:6 278
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tolerated with the most common side effects being headache, 
myalgias, and flushing.58 A second study published using the 
initial PHIRST data showed that patients receiving 40 mg 
daily of tadalafil for PAH had significant improvements in 
quality of life compared with placebo.59 Self-reported health 
status and patient reported health-related quality of life using 
the Short Form 36 (SF-36) and EuroQOL (EQ-5D) were 
measured at baseline, week 8 and week 16. Interestingly, 
improvements observed in 6MWT did not correlate with 
improvements in quality of life measures.
There remain several unanswered questions regarding 
the use tadalafil in PAH. Mortality benefit for PAH which 
has only been shown only with the use of epoprostenol, is 
not known for tadalafil or other PDE5 inhibitors.14,15 Small 
sample size, short trial duration, and the relative rarity of 
PAH has made studying survival challenging. A recent meta-
analysis examining the impact of treatment on PAH utiliz-
ing prostanoids, ERAs, and PDE5 inhibitors was recently 
published.60 Twenty-one randomized controlled trials were 
included in the analysis which showed an overall relative 
risk of mortality of 0.57 (0.35, 0.93) when receiving PAH 
specific therapy compared with placebo. Subset analysis 
revealed 5 RCTs which utilized PDE5 inhibitors (all using 
sildenafil – PHIRST data not included). There was a relative 
risk of death of 0.39 (0.14, 1.05) compared with placebo 
when patients were given PDE5 inhibitors, which nearly met 
statistical significance. This meta-analysis, while provocative, 
is limited by the relatively short duration of included studies 
and caution must be made in attributing a potential survival 
benefit to the use of tadalafil for PAH as the PHIRST data 
were not included.
Conclusion
The availability of several classes of PAH specific medica-
tions has revolutionized the treatment of PAH over the past 
























































Figure 1 Change in 6-minute walk distance over 16 weeks, tadalafil versus placebo: results of a 16-week randomized placebo controlled trial of tadalafil for the treatment 
of pulmonary artery hypertension. Significant improvements in 6-minute walk distance were observed in patients receiving 10, 20 and 40 mg daily of tadalafil compared with 
placebo.
Notes: P = 0.047, 0.028, and 0.001, respectively; N = 392 patients, error bars represent 95% confidence intervals. Patients were randomized to one of five groups: placebo, 
2.5 mg, 10 mg, 20 mg, or 40 mg of tadalafil daily. Reproduced with permission from Galiè N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to 
Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22):2894–903.58 Copyright © 2009 Lippincott Williams & Wilkins.Vascular Health and Risk Management 2010:6 279
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quality of life, and survival have transformed the management 
this patient population from that of hopelessness to one of 
great promise. Tadalafil, the first once-daily PDE5 inhibitor 
FDA approved for the treatment of PAH, has been shown to 
improve exercise tolerance, pulmonary hemodynamics, and 
quality of life. The drug is well tolerated and carries with it 
a favorable side effect profile. Preliminary data on its use 
in combination therapy have been promising. Longer-term 
studies examining the durability of its benefits are ongo-
ing. Lastly, the role of tadalafil in patients with pulmonary 
hypertension in groups II–V has not been clearly defined, 
with more studies needed to establish a role, if any, in these 
patient populations.
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